1 citations
,
May 2021 in “InterConf” Post-COVID-19 hair loss is likely due to stress and inflammation.
1 citations
,
January 2021 in “Wits Journal of Clinical Medicine” Long COVID causes lasting symptoms and needs ongoing care.
1 citations
,
July 2018 in “Current Sexual Health Reports” Post-finasteride Syndrome causes lasting negative effects, but more research is needed for treatment and risk evaluation.
1 citations
,
August 2015 in “Dermatologic Surgery” A woman's chronic head pain after hair transplant surgery was cured by removing a post-traumatic neuroma.
1 citations
,
June 2014 in “L Endocrinologo” Finasteride can cause lasting sexual and mood issues even after stopping the drug.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Gut bacteria imbalance may cause Post-Finasteride Syndrome symptoms.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Gut bacteria imbalance may cause Post-Finasteride Syndrome symptoms.
March 2026 in “Frontiers in Oncology” Dermatologists should focus on restoring skin health and well-being in cancer survivors.
March 2026 in “Actas Dermo-Sifiliográficas” Most dermatologists think post-finasteride syndrome is rare, possibly psychiatric, and needs more research.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” There is no proven treatment for post-finasteride syndrome yet.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Gut bacteria overgrowth may cause some Post-Finasteride Syndrome symptoms.
February 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Gut bacteria overgrowth may cause some Post-Finasteride Syndrome symptoms.
January 2026 in “Journal of Contemporary Medicine” Vitamin D may help prevent or reduce hair loss after COVID-19.
January 2026 in “Medico Research Chronicles” Homeopathy helped improve hair thinning after COVID-19.
January 2026 in “British Journal of Clinical Pharmacology” Serenoa repens may cause long-lasting sexual and psychiatric side effects.
December 2025 in “Cureus” Post-COVID syndrome symptoms are common and overlap with general health issues.
December 2025 in “Cosmetics” Nanocarriers can improve skin treatments after cancer therapy by enhancing antioxidant delivery and effectiveness.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Current drug safety systems fail to detect long-term side effects, needing improvements to protect health and trust.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Current drug safety systems fail to detect long-term side effects, leading to preventable health issues.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Post-drug syndromes are often overlooked, and better systems and education are needed to improve drug safety.
November 2025 in “Journal of Disease and Public Health” Post-COVID-19 syndrome is complex, affects 5%-10% of people, and requires better research and global collaboration for treatment.
October 2025 in “Dermatology Practical & Conceptual” Severe COVID-19 often leads to hair loss in India.
October 2025 in “Journal of Pharmacy And Bioallied Sciences” Post-COVID, many patients experience skin issues like hair loss and herpes reactivation, especially in middle-aged women.
October 2025 in “Cermin Dunia Kedokteran” Proper management of PTSD with psychotherapy and medication can reduce symptoms.
September 2025 in “Journal of the American Academy of Dermatology” Vitiligo may be linked to stopping finasteride.
August 2025 in “International Journal of Clinical Dermatology” A new skin cancer can develop where shingles once occurred.
COVID-19 can trigger a relapsing form of hair loss, requiring long-term treatment strategies.
Allopregnanolone may help reduce inflammation and symptoms related to post-finasteride syndrome.
June 2025 in “Basrah Researches Sciences” Medicinal plants might help with post-COVID-19 issues, but more research is needed.
May 2025 in “Journal of Cosmetic Dermatology” Post-finasteride syndrome may be linked to pre-existing psychological issues, not just the drug.